SOURCE: RxElite, Inc.

July 07, 2008 08:30 ET

RxElite, Inc. Announces Implementation of Preferred Contract Awarded With Heritage Valley Health System for Their Anesthetic Gas Products

MERIDIAN, ID--(Marketwire - July 7, 2008) - RxElite, Inc. (OTCBB: RXEI) is pleased to announce it has completed implementation of the contract, and has received orders from Heritage Valley Health Systems, for their anesthetic gas products. RxElite was awarded a preferred contract listing in all classes of trade for Sevoflurane (Sojourn™) and Isoflurane (Terrell™) on March 3, 2008. Sevoflurane is the most commonly used anesthetic gas in the U.S. and Isoflurane continues to hold share in the anesthetic gas market.

"We are excited to partner with Heritage Valley and do our part in helping our customers lower costs in the current economic environment. The agreement has already begun to yield cost savings to their health system," stated Jonathan Houssian, the CEO of RxElite.

About RxElite, Inc.

RxElite, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), complex active pharmaceutical ingredients, and other specialty areas. www.RxElite.com

About Heritage Valley Health System

Heritage Valley Health System provides comprehensive health care for residents of Allegheny, Beaver, Butler and Lawrence counties, in Pennsylvania; eastern Ohio; and the panhandle of West Virginia. In partnership with more than 400 physicians, Heritage Valley offers a broad range of medical, surgical and diagnostic services at its two hospitals, Heritage Valley Beaver, and Heritage Valley Sewickley; in physician offices; and community satellite facilities. Additional information about Heritage Valley Health System is available online at www.heritagevalley.org.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.

Contact Information

  • For more information:

    Corporate Information
    US T: (208) 288-5550
    Toll Free: (800) 414-1901
    F: (208) 288-1191

    Investor Relations
    Ric Tener
    T: (208) 288-5550
    Fax: (208) 288-1191
    Email: Email Contact